Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s15010-020-01448-x http://scihub22266oqcxt.onion/10.1007/s15010-020-01448-x 32418190!7229436!32418190     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Infection 2020 ; 48 (5): 779-782 Nephropedia Template TP {{tp|p=32418190|t=2020. Early experience with remdesivir in SARS-CoV-2 pneumonia |pdf=|usr=}}{{32418190}} gab.com Text Early experience with remdesivir in SARS-CoV-2 pneumonia JO: Infection http://www.kidney.de/pget.php?&tw=1&pmid=32418190 #FOAvip At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19. Twit Text FOAVip Early experience with remdesivir in SARS-CoV-2 pneumonia ????Infection http://www.kidney.de/pget.php?&tw=1&pmid=32418190 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32418190 #FOAvip English Wikipedia <ref>{{Cite pmid|32418190}}</ref> Early experience with remdesivir in SARS-CoV-2 pneumonia #MMPMID32418190 Durante-Mangoni E; Andini R; Bertolino L; Mele F; Florio LL; Murino P; Corcione A; Zampino R Infection 2020[Oct]; 48 (5): 779-782 PMID32418190show ga At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19. |Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & derivatives[MESH] |Alanine/administration & dosage/adverse effects/*analogs & derivatives[MESH] |Antiviral Agents/*administration & dosage/adverse effects[MESH] |Betacoronavirus/*drug effects/immunology[MESH] |COVID-19[MESH] |Chemical and Drug Induced Liver Injury/diagnosis/etiology/physiopathology/virology[MESH] |Convalescence[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Critical Illness[MESH] |Darunavir/administration & dosage/adverse effects[MESH] |Drug Administration Schedule[MESH] |Drug Combinations[MESH] |Fatal Outcome[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage/adverse effects[MESH] |Lopinavir/administration & dosage/adverse effects[MESH] |Multiple Organ Failure/chemically induced/diagnosis/physiopathology/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |RNA, Viral/*blood[MESH] |Ritonavir/administration & dosage/adverse effects[MESH] |SARS-CoV-2[MESH]Early experience with remdesivir in SARS-CoV-2 pneumonia (epmc).pdf DeepDyve Pubget Overpricing